Radiation Dose Distribution and Quality of Life in Pediatric Brain Tumor Survivors

Overview

This study from the Pediatric Proton/Photon Consortium Registry (PPCR) investigates the relationship between radiation dose to brain substructures and health-related quality of life (HRQoL) in children treated with proton beam therapy (PBT) for primary brain tumors. Findings highlight the impact of radiation dose distribution on HRQoL outcomes measured by patient-reported outcome measures (PROMs).

Background

Survivors of childhood brain tumors often experience impaired HRQoL due to treatment-related adverse effects. Radiotherapy, while essential, can cause chronic health conditions depending on dose, fractionation, and volume of normal tissue irradiated. Proton beam therapy is increasingly used to reduce normal tissue exposure compared to photon therapy. However, the association between radiation dose to specific brain structures and HRQoL in pediatric brain tumor survivors remains unclear. This study aims to fill that knowledge gap using prospectively collected data from the PPCR.

Data Highlights

The study included children under 22 years treated with PBT and with at least two years of follow-up HRQoL data. HRQoL was assessed using the Pediatric Quality of Life Inventory (PedsQL) 4.0 Generic Core Scales and Infant Scales, capturing physical, emotional, social, and school functioning domains. Radiation dosimetry data were derived from clinically delivered treatment plans, with mean and maximum doses calculated for intracranial substructures. Statistical analyses included comparisons to healthy cohorts and longitudinal mixed models to evaluate HRQoL changes over time.

Key Findings

• Higher radiation doses to critical brain substructures are associated with poorer HRQoL outcomes in pediatric brain tumor survivors.
• Proton beam therapy allows for better sparing of normal tissues, potentially reducing adverse effects impacting HRQoL compared to photon therapy.
• Patient-reported outcome measures (PedsQL) provide essential insights into the direct impact of treatment on children's quality of life beyond clinical toxicity assessments.
• Standardized reporting of radiotherapy variables including dose, modality, and field extent is crucial for comprehensive HRQoL analysis.
• Longitudinal HRQoL data reveal changes over time, emphasizing the need for ongoing monitoring of survivors.

Clinical Implications

Clinicians should consider radiation dose distribution to critical brain structures when planning proton beam therapy to minimize long-term impacts on quality of life. Incorporating standardized patient-reported outcome measures into routine follow-up can improve understanding of treatment effects and guide supportive care. Optimizing radiotherapy plans to spare normal tissues may enhance survivorship outcomes in pediatric brain tumor patients.

Conclusion

This study underscores the importance of radiation dose distribution on HRQoL in pediatric brain tumor survivors treated with proton therapy. Integrating dosimetric data with patient-reported outcomes provides valuable insights to optimize treatment and survivorship care.

References

1. PPCR Study Protocol and Data Collection Methods
2. PedsQL Validation Studies
3. Radiotherapy Dose and Toxicity Literature